For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com
Daiichi Sankyo Announces Japanese Research Partners Selected for 2016 TaNeDS Collaborative Drug Discovery Project
Tokyo, Japan (November 30, 2016)－ Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners in Japan for its 2016 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project.
TaNeDS, which began in 2011 as part of Daiichi Sankyo’s open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon initiate collaborative research with this year’s selected parties.
1. Total entries: 209
2. Selected parties: 21
3. Selections by entry type
|
Project type
|
Entries
|
Passed second selections
|
Final selections
|
|
Total
|
209*
|
26
|
21
|
|
a. Drug discovery target verification
|
123
|
14
|
10
|
|
b. Drug discovery target investigation
|
49
|
2
|
2
|
|
c. Drug discovery technology development/verification
|
73
|
8
|
8
|
|
d. Pharmaceutical technology
|
8
|
2
|
1
|
* Project type contains 4 categories, thus entries with multiple categories are counted once for each category.
4. Selections by research theme
|
Desired research themes
|
Entries
|
Passed second selections
|
Final
selections
|
|
Total
|
209*
|
26
|
21
|
|
・Oncology
|
131
|
8
|
5
|
|
・Other disorders
|
77
|
9
|
8
|
|
・Regenerative medicine/cell therapy
|
22
|
1
|
1
|
|
・Chemical biology
|
3
|
0
|
0
|
|
・Biologics
|
23
|
1
|
1
|
|
・DDS
|
15
|
1
|
1
|
|
・Pathological model/unique cell-based assays/vital imaging
|
4
|
0
|
0
|
|
・In silico models related to drug effect estimates/pathological clarification
|
8
|
2
|
2
|
|
・ADME (Drug Absorption, Distribution, Metabolism, Excretion)
|
17
|
1
|
1
|
|
・Drug safety
|
2
|
0
|
0
|
|
・Measuring technology related to biomarkers
|
8
|
1
|
1
|
|
・Structure-based-drug-discovery
|
1
|
0
|
0
|
|
・Pharmaceutical Formulation technology research
|
3
|
2
|
1
|
|
・Drug analysis technology
|
0
|
0
|
0
|
|
・Industrial chemical synthetic technology
|
5
|
0
|
0
|
* Entries with multiple themes are counted once for each theme.
For more information about the TaNeDS program, please visit the Daiichi Sankyo corporate website (in Japanese):
https://www.daiichisankyo.co.jp/corporate/rd/taneds/